The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry.
5-azacytidine
chromosome 17 abnormality
myelodysplastic syndrome
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
08
09
2018
revised:
28
12
2018
accepted:
12
02
2019
pubmed:
22
3
2019
medline:
1
7
2020
entrez:
22
3
2019
Statut:
ppublish
Résumé
In patients with myelodysplastic syndrome (MDS), the prognostic significance of chromosome 17 abnormalities has not yet been fully elucidated, except for isochromosome 17q that has been characterized as an intermediate risk abnormality in the Revised International Prognostic Scoring System (IPSS-R). To further characterize the prognostic significance of chromosome 17 abnormalities we analyzed the hematologic and prognostic characteristics of 548 adult patients with MDS treated with 5-azacytidine through the Hellenic 5-azacytidine registry and found 32 patients with a chromosome 17 abnormality (6 with i[17q], 15 with -17, 3 with add[17p] and the rest with other rarer abnormalities, mostly translocations). The presence of a chromosome 17 abnormality was correlated with poor prognostic features (high IPSS, IPSS-R, and WPSS scores) and a low overall survival rate (15.7 vs 36.4 months for patients without chromosome 17 abnormalities, Kaplan-Meier, Log Rank P < 0.00001), but these results were confounded by the fact that most (92.3%) of the cases with a chromosome 17 abnormality (with the exception of i(17q) that was found in all cases as an isolated abnormality) were found in the context of a complex karyotype. Nevertheless, one should not ignore the contribution of chromosome 17 abnormalities to the prognostic significance of a complex karyotype since 33.8% of complex karyotypes encompassed a chromosome 17 abnormality.
Identifiants
pubmed: 30897290
doi: 10.1002/cam4.2090
pmc: PMC6536924
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Azacitidine
M801H13NRU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2056-2063Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Br J Haematol. 2003 Jun;121(5):815-6
pubmed: 12780798
Haematologica. 2005 Sep;90(9):1168-78
pubmed: 16154839
N Engl J Med. 2016 Nov 24;375(21):2023-2036
pubmed: 27959731
Leuk Res. 2013 Jul;37(7):769-76
pubmed: 23639672
Cancer Genet Cytogenet. 2006 Apr 15;166(2):189-90
pubmed: 16631479
Srp Arh Celok Lek. 2004 Jan-Feb;132(1-2):10-3
pubmed: 15227958
Haematologica. 2003 Jun;88(6):714-5
pubmed: 12801850
Blood. 2007 Dec 15;110(13):4385-95
pubmed: 17726160
Leukemia. 2016 Mar;30(3):666-73
pubmed: 26514544
Br J Haematol. 2013 Mar;160(5):660-72
pubmed: 23297687
Ann Hematol. 2010 Jul;89(7):671-9
pubmed: 20179929
Blood. 1999 Jul 1;94(1):225-32
pubmed: 10381517
Am J Hematol. 2018 Jul;93(7):895-901
pubmed: 29659040
Cancer Med. 2019 May;8(5):2056-2063
pubmed: 30897290
Cancer. 2012 Jun 1;118(11):2879-88
pubmed: 22038701
Br J Haematol. 2002 Oct;119(1):87-96
pubmed: 12358907
Br J Haematol. 2000 Feb;108(2):346-56
pubmed: 10691865